聴覚障害,補聴器の使用,および認知症患者における神経精神症状:NACCの調査結果
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。聴覚障害は認知症では一般的ですが,神経精神症状 (NPS) と関連していません. しかし 認知症患者の補聴器の使用は NPSの数と重症度を大幅に低下させ 聴覚ケアが重要な介入であることを示唆しています
科学分野
- ゲロントロジー
- 神経科学
- 聴覚学
背景
- 聴覚障害は認知症 (PLWD) を患っている人の90%以上に影響します.
- 聴覚障害を含む感覚障害は,神経精神症状 (NPS) の増加と関連しています.
- 補聴器の使用は,NPSに対する保護効果を提供することがあります.
研究 の 目的
- PLWDにおける機能性聴覚障害とNPSとの関連を調査する.
- 補聴器の使用が聴覚障害のあるPLWDにおけるNPSの数と重症度に与える影響を調べる.
主な方法
- ナショナル・アルツハイマー・コーディネーション・センターの ユニフォーム・データセットの横断分析
- 関連性を推定するために使用される負の二項回帰は,人口統計学的および臨床的要因を調整します.
- 補聴器の使用における選択バイアスを解決するために採用された近隣のマッチング.
主要な成果
- 10,054人の参加者のうち,24%が聴覚障害を報告し,聴覚障害はNPSと有意に関連していなかった.
- 聴覚障害のあるPLWD患者の54. 8%が補聴器を使用した.
- 補聴器の使用は,マッチングと調整後のNPSの減少と減少と関連していました.
結論
- 補聴器の使用は,PLWDにおけるNPSの管理のための非薬学的介入の不足である可能性があります.
- 聴覚ケアは NPSの非薬学的な管理のための有望な戦略として浮上しています
- 認知症の治療における聴覚の介入のさらなる探求は正当化されています.
関連する概念動画
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
When we hear a sound, our nervous system is detecting sound waves—pressure waves of mechanical energy traveling through a medium. The frequency of the wave is perceived as pitch, while the amplitude is perceived as loudness.
Sound waves are collected by the external ear and amplified as they travel through the ear canal. When sounds reach the junction between the outer and middle ear, they vibrate the tympanic membrane—the eardrum. The resulting mechanical energy causes the...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...